Nuveen Asset Management LLC Has $1 Million Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Nuveen Asset Management LLC grew its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 28.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,957 shares of the company’s stock after acquiring an additional 11,866 shares during the period. Nuveen Asset Management LLC owned 0.18% of RAPT Therapeutics worth $1,002,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of RAPT. Canada Pension Plan Investment Board acquired a new stake in RAPT Therapeutics during the 1st quarter worth about $1,554,000. Teachers Retirement System of The State of Kentucky grew its holdings in RAPT Therapeutics by 43.1% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 35,528 shares of the company’s stock worth $789,000 after acquiring an additional 10,704 shares during the period. Alliancebernstein L.P. grew its holdings in RAPT Therapeutics by 91.8% during the 2nd quarter. Alliancebernstein L.P. now owns 28,000 shares of the company’s stock worth $890,000 after acquiring an additional 13,400 shares during the period. New York State Common Retirement Fund grew its holdings in RAPT Therapeutics by 53.4% during the 2nd quarter. New York State Common Retirement Fund now owns 15,490 shares of the company’s stock worth $492,000 after acquiring an additional 5,390 shares during the period. Finally, Los Angeles Capital Management LLC grew its holdings in RAPT Therapeutics by 4.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 18,352 shares of the company’s stock worth $583,000 after acquiring an additional 790 shares during the period. Hedge funds and other institutional investors own 97.62% of the company’s stock.

In related news, insider William Ho sold 3,000 shares of RAPT Therapeutics stock in a transaction that occurred on Wednesday, September 8th. The shares were sold at an average price of $36.04, for a total value of $108,120.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Group Ii Lp Column sold 9,239 shares of RAPT Therapeutics stock in a transaction that occurred on Monday, September 27th. The stock was sold at an average price of $34.57, for a total transaction of $319,392.23. The disclosure for this sale can be found here. Insiders sold a total of 91,477 shares of company stock worth $3,291,721 in the last ninety days. 26.34% of the stock is currently owned by insiders.

Several brokerages have recently commented on RAPT. SVB Leerink restated a “buy” rating on shares of RAPT Therapeutics in a research note on Monday, October 4th. Zacks Investment Research upgraded RAPT Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 2nd. Cantor Fitzgerald reduced their target price on RAPT Therapeutics from $71.00 to $58.00 and set an “overweight” rating for the company in a research note on Tuesday, November 16th. Finally, HC Wainwright restated a “buy” rating and issued a $56.00 target price on shares of RAPT Therapeutics in a research note on Monday, August 30th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $60.17.

RAPT Therapeutics stock opened at $31.16 on Monday. RAPT Therapeutics, Inc. has a 52 week low of $14.89 and a 52 week high of $43.26. The company’s 50 day moving average price is $33.84 and its two-hundred day moving average price is $31.28. The stock has a market cap of $920.65 million, a P/E ratio of -12.77 and a beta of 0.12.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Wednesday, November 10th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01). RAPT Therapeutics had a negative return on equity of 41.61% and a negative net margin of 1,468.46%. As a group, sell-side analysts expect that RAPT Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.

RAPT Therapeutics Profile

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Recommended Story: What is a put option?

Institutional Ownership by Quarter for RAPT Therapeutics (NASDAQ:RAPT)